Surrozen, Inc./DE (SRZNW)

↓ Download CSV

CIK 0001824893 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Surrozen, Inc./DE reported revenue of $3.48M, down 67.4% from the prior year. The company ran a net loss, with a net margin of -6960.8%. It held $98.73M in total assets against $286.49M in total liabilities.

Key ratios (FY2025)

-1210.6%
Operating margin
-6960.8%
Net margin
-67.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$3.48M$10.65M$0$12.50M$0
Operating Income-$42.09M-$25.54M-$45.78M-$44.34M-$54.39M-$32.81M
Net Income-$242.03M-$63.56M-$43.04M-$36.00M-$54.65M-$32.72M
EPS (Diluted)$-32.37$-21.67$-21.33$-15.56$-2.21
Total Assets$98.73M$48.47M$46.08M$89.44M$137.17M$62.06M
Total Liabilities$286.49M$69.85M$8.14M$13.43M$27.47M$14.77M
Shareholders' Equity-$187.76M-$21.38M$37.94M$76.00M$109.70M$47.29M$29.39M
Cash & Equivalents$89.25M$34.56M$36.04M$24.69M$33.09M$34.98M
Operating Cash Flow-$30.24M-$17.63M-$40.36M-$44.15M-$48.81M-$29.10M
Capital Expenditures$128.0K$26.0K$398.0K$728.0K$1.27M$874.0K
Shares Outstanding9.78M3.26M2.06M2.01M35.03M18.26M